Recently, TCF1 has been described as a marker of a stem-cell-like subset of CD8 T cells associated with improved anti-tumor immunity and response to immune-checkpoint blockade (Sade-Feldman et al., 2018; Siddiqui et al., 2019). The gene discussed is CD8A; the disease is neoplasm.